VistaGen Therapeutics (VTGN) – Analysts’ Recent Ratings Updates

by · The Markets Daily

A number of research firms have changed their ratings and price targets for VistaGen Therapeutics (NASDAQ: VTGN):

  • 12/20/2025 – VistaGen Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
  • 12/17/2025 – VistaGen Therapeutics had its “hold” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $0.90 price target on the stock, down previously from $15.00.
  • 12/17/2025 – VistaGen Therapeutics had its “hold” rating reaffirmed by analysts at Maxim Group.
  • 12/17/2025 – VistaGen Therapeutics had its “market perform” rating reaffirmed by analysts at William Blair.
  • 12/17/2025 – VistaGen Therapeutics was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $1.00 price target on the stock.
  • 11/17/2025 – VistaGen Therapeutics was given a new $12.00 price target on by analysts at Stifel Nicolaus.

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.

Featured Articles